Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07345338Not ApplicableNot Yet Recruiting

Mainstreaming Genetic Testing for Non-Ischemic Cardiomyopathy in Western Canada

Role: collaborator

NCT03831256Not ApplicableActive Not Recruiting

PErsonalized Genomics for Prenatal Abnormalities Screening USing Maternal Blood

Role: collaborator

NCT06560606Recruiting

UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease

Role: collaborator

NCT03070067Completed

SpecTRA; A Study of the Validation of Protein Biomarkers in Transient Ischemic Attack

Role: collaborator

NCT03050099Completed

SpecTRA; An Observational Study of the Verification of Protein Biomarkers in Transient Ischemic Attack.

Role: collaborator

All 5 trials loaded